Financial PerformanceTransMedics reported strong first-quarter results, as sales increased roughly 48% during the period, to $143.5 million, beating the Street’s $123.7 million expectation.
Market AdoptionOCS utilization, particularly within liver, has been ramping nicely where both penetration and adoption metrics have trended upward.
Revenue GuidanceManagement increased its 2025 guidance, now projecting top-line growth of roughly 30% at the midpoint ($575 million).